Menu
← Oncology Approval Tracker
FDA DECISION ·
Tevimbra
tislelizumab-jsgr · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds 400 mg IV every six weeks with platinum-containing chemotherapy for first-line unresectable or metastatic ESCC with tumor PD-L1 expression of at least 1.
LAMPGEN ANALYSIS
Why it matters
This action adds a longer interval to the existing first-line chemotherapy combination indication.
What research teams should watch
Specify which assessments remain linked to chemotherapy and which align with checkpoint dosing.
PRIMARY RECORDS